41
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition(s):LymphomaLast Updated:November 27, 2019Terminated
Brentuximab Vedotin: 159 Clinical Trials, Page 5 of 16
Hide Studies Not Open or Pending
42
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
Condition(s):Graft Versus Host DiseaseLast Updated:June 27, 2013Withdrawn
43
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Condition(s):LymphomaLast Updated:September 20, 2019Recruiting
44
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Condition(s):Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic MastocytosisLast Updated:January 29, 2019Completed
45
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
Condition(s):Systemic Lupus ErythematosusLast Updated:June 11, 2018Terminated
46
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Condition(s):Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell LymphomaLast Updated:June 20, 2019Recruiting
47
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Condition(s):PTLD; Lymphoid Tumor; Hematopoietic/Lymphoid Cancer; Plasmacytic Hyperplasia PTLD; Infectious Mononucleosis; Florid Follicular Hyperplasia PTLD; Polymorphic PTLD; Monomorphic PTLD; Classical Hodgkin Lymphoma Type PTLDLast Updated:October 25, 2019Not yet recruiting
48
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition(s):LymphomaLast Updated:October 17, 2018Terminated
49
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition(s):Recurrent Adult Hodgkin Lymphoma; Recurrent Childhood Hodgkin Lymphoma; Refractory Childhood Hodgkin LymphomaLast Updated:June 12, 2020Active, not recruiting
50
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Condition(s):Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Anemia, Refractory, With Excess of Blasts; Solid TumorsLast Updated:March 4, 2016Completed